Arbaclofen ER Tablets ( DrugBank: Arbaclofen )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
13 | 多発性硬化症/視神経脊髄炎 | 3 |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05179577 (ClinicalTrials.gov) | June 2023 | 12/11/2021 | A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006) | Spasticity | Drug: Arbaclofen;Drug: Placebo | RVL Pharmaceuticals, Inc. | NULL | Not yet recruiting | 18 Years | 65 Years | All | 442 | Phase 3 | NULL |
2 | NCT02869425 (ClinicalTrials.gov) | July 2016 | 3/8/2016 | To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS | A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis | Multiple Sclerosis;Sperm | Drug: arbaclofen ER Tablets;Drug: Placebo for arbaclofen ER tablets | RVL Pharmaceuticals, Inc. | Osmotica Pharmaceutical US LLC | Withdrawn | 18 Years | 55 Years | Male | 0 | Phase 3 | United States |
3 | NCT01743651 (ClinicalTrials.gov) | November 2012 | 28/11/2012 | Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis | A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis | Spasticity;Multiple Sclerosis | Drug: arbaclofen;Drug: baclofen;Drug: Placebo | RVL Pharmaceuticals, Inc. | Osmotica Pharmaceutical US LLC | Completed | 18 Years | 65 Years | All | 353 | Phase 3 | United States;Russian Federation;Ukraine |